SMS Pharmaceuticals Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - There is no discussion of any capital raising activities in the Q1 FY23 earnings call held on August 18, 2022. - The management focuses on commercial expansion, product launches, and improving profitability without mentioning any new funding rounds. - Capex and R&D investments are being managed internally without indication of external fundraising. - Hence, based on available information, no new debt or equity fundraising is planned or announced as of this call.

- No explicit mention of new or upcoming CAPEX or capital investments in the transcript. - CFO Vamsi Krishna Potluri noted that depreciation remained nominal in FY23, as major capitalization happened in FY22, indicating limited new CAPEX in the current fiscal year. - The company is focusing on commercializing new products (e.g., Sitagliptin, Ibuprofen) and expanding R&D (planned growth of 20% in R&D spend in FY23). - Emphasis placed on strategic investments in product launches, geographic expansion, and customer addition rather than heavy capital expenditure. - Inventory build-up was noted for launching Sitagliptin and COVID-related drugs, but raw material purchases and major CAPEX are under control. - Overall, strategic focus is on operational expansion rather than announced large-scale capital investments at this time.

- Ibuprofen is a flagship product with recent CEP approval, enabling sales in European markets and expected to generate good revenues going forward. - Targeting 30-35% growth in Ibuprofen contribution. - Plans to add 8 to 10 new products to the portfolio in the next year to increase non-ARV product revenue share. - Sitagliptin launch is recent; Indian market estimated around 150+ tons, offering significant opportunity. - The company is focused on expanding market share domestically and internationally, especially for newly launched products. - ARV product Tenofovir contributes around 35% of revenue; sales depend on tender outcomes with some growth potential. - Joint Venture (JV) products could contribute 20-25% of revenue, up from around 15%. - Overall, non-ARV products are positioned for significant growth to diversify revenue and reduce dependence on ARV APIs. - FY23 is expected to see improved capacity utilization and sales volumes, with EBITDA and PAT positive turnaround targeted.

- The company is optimistic about turning EBITDA positive by end of Q2 FY23 and PAT positive by end of FY23 (Page 12). - Strong focus on commercializing Ibuprofen in Europe after CEP approval, targeting significant revenue growth (Pages 6, 13). - Ibuprofen revenue contribution could grow to 35-40% of the top line by FY23-24 (Page 6). - Growth expected from newly launched products such as Sitagliptin with an India market size assumption of around 150 tons and targeting good market share (Pages 14-15). - ARV product Tenofovir sales remain uncertain due to tender dependencies; company working to diversify product mix to reduce dependence on ARV (Pages 12, 15). - Launches from JV expected to contribute 20-25% of revenue, with focus on new products post-patent expiry (Page 8). - R&D expenses expected to increase by about 20% in FY23, supporting new product launches (Page 4). - Overall, the company is confident of overcoming short-term challenges and plans steady revenue and profitability growth through new product launches, customer additions, and geographical expansion (Pages 3-4).

- The company is currently facing difficulty in predicting orderbook due to delays and uncertainty in government tenders, especially in the ARV segment. - Clarity on ARV orders and tender outcomes is expected by the next quarter. - Inventory buildup (approx. ₹275 crore) is partly due to readiness for product launches like Sitagliptin and Molnupiravir. - The company is actively pushing partners for demand forecasts and contract manufacturing projections. - Ibuprofen and other products are gaining traction, with aims to increase capacity utilization from 22% in Q1 to 70-80% by Q4 FY23. - New product launches (including Sitagliptin in India) provide significant revenue potential and order flow opportunities. - The business is focused on diversifying revenue streams beyond ARV products and expanding into domestic and international markets.